The purpose of this study is to validate the anti-müllerian hormone (AMH) cut-off established and validated in the APHRODITE study, for the determination of PCOM as part of the diagnosis of PCOS, using the Elecsys AMH Plus immunoassay.

The study participants will be women born July 1985-Dec 1987 in Northern Finland; the study partially links to the Northern Finland Birth Cohort 1986. Female subjects included in this cohort will be invited to participate in the study with the aim to enroll up to 1800 subjects. Each enrolled subject will have one study visit, where the clinical data required for assessing their PCOS status will be recorded, including a gynecological examination by transvaginal ultrasound to determine polycystic ovarian morphology (PCOM) status (antral follicle count and ovarian volume). Study subjects will also have blood drawn for serum collection, where hormonal parameters relevant for PCOS will be measured. The collected serum will also be used to measure the AMH levels using the Roche Elecsys AMH test.

Inclusion Criteria:

• Female
• Born July 1985-Dec 1987 in Northern Finland
• Signed informed consent regarding ROCHE collaboration

Exclusion Criteria:

• Unwilling to undergo gynecological examination including transvaginal ultrasound (TVUS)
• Unwilling to have blood drawn
• Pregnancy

Subjects born in Northern Finland in July 1985- December 1987 who were assigned female at birth and currently register as females.

As the study is population-based, all non-pregnant women born in Northern Finland between July 1985-December 1987 will be invited to participate in the study. Most women will be white with a small minority (estimated below 3%) of indigenous Sámi people.

Data will be deposited into the Arctic Biobank as part of the Northern Finland Birth Cohort 1986 data.

Data is available on request 10 years from study completion

Data available according to policies of the NFBC.